ClinicalTrials.gg
CompletedNCT07943546PRIME-HTN-BHUTUpdated Nov 17, 2026

"PhaRmacist-led Intervention for Medication adherencE and Clinical Outcomes Among HyperTenSive Patients With Comorbidities in BHUTAN (PRIME-HTN-BHUTAN).

An interventional study of Pharmacist-Led Counseling and education for Hypertension Management in Hypertension (HTN), sponsored by Naresuan University. Completed at 1 site in Bhutan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Naresuan University · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study aimed to evaluate changes in medication adherence, blood pressure, and health-related quality of life following a pharmacist-led intervention among hypertensive patients with comorbidities in Bhutan.

A single-group, pre-post quasi-experimental study was conducted at Phuentsholing General Hospital, Bhutan. Participants received pharmacist-led counseling and education focusing on hypertension management, medication adherence, prevention of complications, and lifestyle modifications. Assessments were conducted at three time points: baseline, first follow-up (approximately two months), and second follow-up (approximately four months).

Medication adherence was assessed using the Adherence to Refills and Medications Scale (ARMS), while blood pressure was measured using an automated blood pressure monitoring device. Health-related quality of life was evaluated using the EQ-5D-5L questionnaire and EQ Visual Analogue Scale (EQ-VAS). Changes in these outcomes were assessed across the three assessment periods.

The study was designed to provide evidence on changes in medication adherence, clinical outcomes, and health-related quality of life associated with pharmacist-led counseling and education among hypertensive patients with comorbidities in Bhutan.

Read the detailed description

Hypertension is a major public health concern and an important risk factor for cardiovascular disease, stroke, and kidney complications. Its management becomes increasingly challenging among patients with comorbidities because of complex medication regimens, multiple treatment requirements, and the need for sustained lifestyle modifications. Medication nonadherence may further compromise blood pressure management and overall health outcomes. In Bhutan, strengthening patient-centered approaches to chronic disease management is particularly relevant to improving the quality of care for individuals with hypertension and coexisting chronic conditions.

Pharmacists can contribute to hypertension management through medication counseling, patient education, identification of medication-related concerns, and reinforcement of appropriate medication-taking behaviors. However, evidence regarding pharmacist-led interventions among hypertensive patients with comorbidities in Bhutan remains limited. This study was undertaken to examine the potential role of structured pharmacist-led counseling and education within routine healthcare services.

The intervention consisted of individualized counseling delivered by the principal investigator, focusing on understanding hypertension, the importance of consistent medication use, potential complications of uncontrolled blood pressure, and practical strategies to improve medication adherence. Participants were also educated about lifestyle modifications, including dietary practices, physical activity, and other behaviors relevant to hypertension management. An educational brochure was used to reinforce key information and support participants' understanding of their condition and treatment.

02

Conditions studied

  • Hypertension (HTN)

Browse trials for

03

In context

Hypertension

6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.

This study's enrollment of 30 is below the median of 100 across 4,582 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

This is the only study on the registry with Naresuan University as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The individual must be diagnosed with hypertension and have been receiving antihypertensive medication for at least 12 months.
  • The individual must be on at least one oral antihypertensive drug, and at least 3 oral medications in total (antihypertensive agent and oral drugs for comorbid conditions).
  • The individual must have one or more chronic comorbidities (NCDs-CVDs, DM, CKD, Dyslipidemia) and taking oral medication for the management of the comorbidity.
  • The individual must have had no change in antihypertensive medication in the previous two months.
  • The individual must not have been admitted to hospital for hypertension in the previous month.
  • The individual must be willing to participate and capable of providing written (signature/thumbprint).
  • The individual must be able to manage their own medications.
  • The individual must be aged 18-70 years.
  • The individual should be able to speak and understand one of these languages (English, Dzongkha, or Lhotshamkha)

Exclusion criteria

Exclusion Criteria:

  • The individuals with terminal illnesses, pregnant or lactating mothers, and individuals with cognitive impairment or a severe physical or sensory disability that would prevent participation were excluded.
  • Patients with secondary hypertension were excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Pharmacist-Led Intervention

    Participants in this single-group study received pharmacist-led counseling and education focused on hypertension management, medication adherence, prevention of complications, and lifestyle modifications. The intervention was delivered at baseline and follow-up visits. Medication adherence, blood pressure, and health-related quality of life were assessed at baseline, first follow-up, and second follow-up.

    Behavioral: Pharmacist-Led Counseling and education for Hypertension Management

Interventions

  • BehavioralPharmacist-Led Counseling and education for Hypertension Management

    A pharmacist-led intervention consisting of individualized counseling and patient education was provided to hypertensive patients with comorbidities. The intervention focused on improving medication adherence, enhancing understanding of hypertension and its complications, emphasizing the importance of regular medication use, and promoting lifestyle modifications. Educational materials covering hypertension management, medication adherence, and healthy lifestyle practices were used to support counseling. The intervention was delivered at baseline and subsequent follow-up visits, approximately two months apart, over a four-month follow-up period. Blood pressure, medication adherence, and health-related quality of life were assessed at baseline, first follow-up, and second follow-up.

06

What researchers measure

Primary outcomes

  1. Change in Medication Adherence

    Change in medication adherence assessed using the Adherence to Refills and Medications Scale (ARMS). Lower scores indicate better medication adherence.

    Time frame: Baseline, 2 months, and 4 months

  2. Change in Blood Pressure

    Change in systolic and diastolic blood pressure, measured in mmHg, from baseline to first and second follow-up assessments.

    Time frame: Baseline, 2 months, and 4 months

Secondary outcomes

  1. Change of EQ-5D-5L Utility Index

    Change in health-related quality of life assessed using the EQ-5D-5L questionnaire, with utility scores calculated using the Indian value set. Higher values indicate better health-related quality of life.

    Time frame: Baseline, 2 months, and 4 months

  2. Change in EQ-VAS Score

    Change in self-reported health status assessed using the EQ Visual Analogue Scale (0-100), with higher scores indicating better perceived health.

    Time frame: Baseline, 2 months, and 4 months

07

Study locations

1 site
  • Phuentsholing General Hospital
    Phuentsholing, Chhukha Dzongkhag 21102, Bhutan
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared due to participant confidentiality and restrictions under the approved research protocol and informed consent.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Aug 2026, 2 months.

Of 1,406 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 2 months is below that.

Counting every sponsor, half of 1,501 studies reached it within 23 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 17, 2026
StartActual
Jun 23, 2026
Primary completionActual
Aug 26, 2026
CompletionActual
Oct 28, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943546
Lead sponsor
Naresuan University
Responsible party
Lalita Powdel (Master's Student (Pharmacist), Naresuan University) — Principal investigator
First posted
Nov 17, 2026
Start date
Jun 23, 2026
Primary completion
Aug 26, 2026
Completion
Oct 28, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion